Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis

Israel Medical Association Journal

Volumn 13, Issue 3, 2011, Pages 147-152

  Kerekes, György ^a   Soltész, Pál ^a   Szucs, Gabriella ^a   Szamosi, Szilvia ^a   Dér, Henriett ^a   Szabó, Zoltán ^a   Csáthy, László ^a   Váncsa, Andrea ^a   Szodoray, Peter ^b   Szegedi, Gyula ^c   Szekanecz, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF OSLO   (Norway)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Adalimumab; Arterial stiffness; Atherosclerosis; Carotid intima media thickness; Endothelial dysfunction; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; IMMUNOGLOBULIN M; RHEUMATOID FACTOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; BRACHIAL ARTERY; CAROTID ATHEROSCLEROSIS; CLINICAL ARTICLE; COMMON CAROTID ARTERY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG RESPONSE; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; MALE; PROTEIN BLOOD LEVEL; PULSE WAVE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VASODILATATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; BRACHIAL ARTERY; CAROTID ARTERY, COMMON; ELASTICITY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; VASCULAR DISEASES; VASODILATION; VON WILLEBRAND FACTOR;

EID: 79954483646     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kerekes G, Szekanecz Z, Dér H, et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of infammation and autoimmunity. J Rheumatol 2008; 35: 398-406.
2. Giles JT, Post W, Blumenthal RS, Bathon JM. Terapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nature Clin Pract Rheumatol 2006; 2: 320-329.
3. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-3347.
4. Szekanecz Z, Kerekes G, Dér H, et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann NY Acad Sci 2007; 1108: 349-358.
5. Kerekes G, Soltész P, Dér H, et al. Efects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann NY Acad Sci 2009; 1173: 814-821.
6. Ross R. Atherosclerosis - an infammatory disease. N Engl J Med 1999; 340: 115-126.
7. Szekanecz Z. Pro-infammatory cytokines in atherosclerosis. IMAJ Isr Med Assoc J 2008; 10: 529-530.
8. Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196: 756-763.
9. Kaplan MJ. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2006; 18: 289-297.
10. Wållberg-Jonsson S, Caidahl K, Klintland N, Nyberg G, Rantapää-Dahlqvist S. Increased arterial stifness and indication of endothelial dysfunction in long-standing rheumatoid arthritis. Scand J Rheumatol 2008; 37: 1-5.
11. Soltész P, Dér H, Kerekes G, et al. A comparative study of arterial stifness, fow-mediated vasodilation of the brachial artery and the thickness of carotid artery intima-media in patients with systemic autoimmune diseases. Clin Rheumatol 2009; 28: 655-662.
12. Mäki-Petäjä KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy. Circulation 2006; 114: 1185-1192.
13. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of infammatory arthritis. Ann Rheum Dis 2010; 69: 325-331.
14. Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, et al. Infuence of anti-TNF-alpha infiximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373-379.
15. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody. Arthritis Rheum 2004; 51: 447-450.
16. Del Porto F, Lagana B, Lai S, et al. Response to anti-tumour necrosis factor α blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 2007; 46: 1111-1115.
17. Wong M, Oakley SP, Young L, et al. Infiximab improves vascular stifness in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1277-1284.
18. Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infiximab. Clin Exp Rheumatol 2006; 24: 309-312.
19. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy. Arthritis Rheum (Arthritis Care Res) 2008; 59: 1821-1824.
20. Kerekes G, Soltész P, Dér H, et al. Efects of rituximab treatment on endothelial dysfunction and lipid profle in rheumatoid arthritis. Clin Rheumatol 2009; 28: 705-710.
21. Baulmann J, Schillings U, Rickert S, et al. A new oscillometric method for assessment of arterial stifness: comparison with tonometric and piezo-electronic methods. J Hypertens 2008; 26: 523-528.
22. Sherer Y, Gerli R, Gilburd B, et al. Tickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus 2007; 16: 259-264.
23. Gerli R, Sherer Y, Bocci EB, et al. Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors. Ann N Y Acad Sci 2007; 1108: 372-381.
24. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of frst cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-1218.
25. Dixon WG, Watson KD, Lunt M, Hyrich KL; British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905-2912.